Pembrolizumab With and Without Radiotherapy for Non-Small Cell Lung Cancer

Summary

This is a randomized single-institution, phase II, open-label clinical trial of neoadjuvant pembrolizumab with or without low-dose stereotactic radiation therapy (SRT) in stage I-IIIA non-small lung cancer (NSCLC) patients who are planned to undergo surgical resection of their lung cancer.

Timeline

Start

2017-10-04

Primary completion

2022-03-31

Completion

2022-03-31

Drugs

Indications